Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Quantification of In Vivo Target Engagement Using Microfluidic Activity-Based Protein Profiling.

Reardon HT, Herbst RA, Henry CL, Herbst DM, Ngo N, Cisar JS, Weber OD, Niphakis MJ, O'Neill GP.

SLAS Technol. 2019 Oct;24(5):489-498. doi: 10.1177/2472630319852303. Epub 2019 Jun 14.

PMID:
31199699
2.

Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators.

Clapper JR, Henry CL, Niphakis MJ, Knize AM, Coppola AR, Simon GM, Ngo N, Herbst RA, Herbst DM, Reed AW, Cisar JS, Weber OD, Viader A, Alexander JP, Cunningham ML, Jones TK, Fraser IP, Grice CA, Ezekowitz RAB, O'Neill GP, Blankman JL.

J Pharmacol Exp Ther. 2018 Dec;367(3):494-508. doi: 10.1124/jpet.118.252296. Epub 2018 Oct 10.

PMID:
30305428
3.

Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.

Cisar JS, Weber OD, Clapper JR, Blankman JL, Henry CL, Simon GM, Alexander JP, Jones TK, Ezekowitz RAB, O'Neill GP, Grice CA.

J Med Chem. 2018 Oct 25;61(20):9062-9084. doi: 10.1021/acs.jmedchem.8b00951. Epub 2018 Aug 23.

PMID:
30067909
4.

Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al.

Brown KT, Do R, Gönen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson K, Garcia AR, Beattie CM, Zhao B, Solomon SB, Schwartz LH, DeMatteo RP, Abou-Alfa GK.

J Clin Oncol. 2017 Jan 10;35(2):258-259. Epub 2016 Oct 23. No abstract available.

PMID:
28056199
5.

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK.

J Clin Oncol. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1.

6.

Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents.

Nagabukuro H, Villa KL, Wickham LA, Kulick AA, Gichuru L, Donnelly MJ, Voronin GO, Pereira T, Tong X, Nichols A, Alves SE, O'Neill GP, Johnson CV, Hickey EJ.

J Pharmacol Exp Ther. 2011 Jul;338(1):220-7. doi: 10.1124/jpet.111.179747. Epub 2011 Apr 1.

PMID:
21459965
7.

Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.

Gallant M, Beaulieu C, Berthelette C, Colucci J, Crackower MA, Dalton C, Denis D, Ducharme Y, Friesen RW, Guay D, Gervais FG, Hamel M, Houle R, Krawczyk CM, Kosjek B, Lau S, Leblanc Y, Lee EE, Levesque JF, Mellon C, Molinaro C, Mullet W, O'Neill GP, O'Shea P, Sawyer N, Sillaots S, Simard D, Slipetz D, Stocco R, Sørensen D, Truong VL, Wong E, Wu J, Zaghdane H, Wang Z.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. doi: 10.1016/j.bmcl.2010.11.015. Epub 2010 Nov 5.

PMID:
21106375
8.

Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist.

Gervais FG, Sawyer N, Stocco R, Hamel M, Krawczyk C, Sillaots S, Denis D, Wong E, Wang Z, Gallant M, Abraham WM, Slipetz D, Crackower MA, O'Neill GP.

Mol Pharmacol. 2011 Jan;79(1):69-76. doi: 10.1124/mol.110.068585. Epub 2010 Oct 13.

PMID:
20943773
9.

Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD.

Devanarayan V, Scholand MB, Hoidal J, Leppert MF, Crackower MA, O'Neill GP, Gervais FG.

COPD. 2010 Feb;7(1):51-8. doi: 10.3109/15412550903499530.

PMID:
20214463
10.

Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma.

Therien AG, Bernier V, Weicker S, Tawa P, Falgueyret JP, Mathieu MC, Honsberger J, Pomerleau V, Robichaud A, Stocco R, Dufresne L, Houshyar H, Lafleur J, Ramachandran C, O'Neill GP, Slipetz D, Tan CM.

Am J Respir Cell Mol Biol. 2008 Jul;39(1):26-35. doi: 10.1165/rcmb.2007-0240OC. Epub 2008 Feb 7.

PMID:
18258919
11.

Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I.

Bernier V, Stocco R, Bogusky MJ, Joyce JG, Parachoniak C, Grenier K, Arget M, Mathieu MC, O'Neill GP, Slipetz D, Crackower MA, Tan CM, Therien AG.

J Biol Chem. 2006 Aug 25;281(34):24704-12. Epub 2006 Jun 20.

12.

The C3a receptor antagonist SB 290157 has agonist activity.

Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y, Lau CK, Friesen RW, O'Neill GP, Gervais FG, Therien AG.

Immunol Lett. 2005 Sep 15;100(2):139-45. Epub 2005 Mar 25.

PMID:
16154494
13.

Percent right ventricular pacing predicts outcomes in the DAVID trial.

Sharma AD, Rizo-Patron C, Hallstrom AP, O'Neill GP, Rothbart S, Martins JB, Roelke M, Steinberg JS, Greene HL; DAVID Investigators.

Heart Rhythm. 2005 Aug;2(8):830-4.

PMID:
16051118
14.

Identification of a potent and selective synthetic agonist at the CRTH2 receptor.

Gervais FG, Morello JP, Beaulieu C, Sawyer N, Denis D, Greig G, Malebranche AD, O'Neill GP.

Mol Pharmacol. 2005 Jun;67(6):1834-9. Epub 2005 Mar 8.

PMID:
15755909
15.

Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa.

Nantel F, Fong C, Lamontagne S, Wright DH, Giaid A, Desrosiers M, Metters KM, O'Neill GP, Gervais FG.

Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):87-101.

PMID:
15165034
16.

Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.

Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP, Gervais FG.

Br J Pharmacol. 2002 Dec;137(8):1163-72.

17.

Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP.

Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, Metters KM, O'neill GP.

J Allergy Clin Immunol. 2001 Dec;108(6):982-8.

PMID:
11742277
18.

The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels.

Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, Robitaille R, Low MJ, O'Neill GP, Metters K, Lacaille JC, Chronwall BM, Morris SJ.

J Pharmacol Exp Ther. 2001 Jul;298(1):15-24.

PMID:
11408520
19.

Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes.

Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, Liu Q, Clements M, Zeng Z, O'Neill GP, Jones TR, Lynch KR, Austin CP, Evans JF.

Am J Respir Crit Care Med. 2001 Jan;163(1):226-33.

PMID:
11208650
20.

Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action.

Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hébert TE.

Mol Pharmacol. 2001 Jan;59(1):144-52.

PMID:
11125035
21.

Characterization of the human cysteinyl leukotriene 2 receptor.

Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF.

J Biol Chem. 2000 Sep 29;275(39):30531-6.

22.

Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GABA(B) heterodimer as the functional receptor.

Sullivan R, Chateauneuf A, Coulombe N, Kolakowski LF Jr, Johnson MP, Hebert TE, Ethier N, Belley M, Metters K, Abramovitz M, O'Neill GP, Ng GY.

J Pharmacol Exp Ther. 2000 May;293(2):460-7.

PMID:
10773016
23.

Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue.

Boie Y, Stocco R, Sawyer N, Greig GM, Kargman S, Slipetz DM, O'Neill GP, Shimizu T, Yokomizo T, Metters KM, Abramovitz M.

Eur J Pharmacol. 1999 Sep 10;380(2-3):203-13.

PMID:
10513580
24.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
25.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

PMID:
10406640
26.

Characterization of the human cysteinyl leukotriene CysLT1 receptor.

Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL Jr, Ford-Hutchinson AW, Caskey CT, Evans JF.

Nature. 1999 Jun 24;399(6738):789-93.

PMID:
10391245
27.

Discovery of a receptor related to the galanin receptors.

Lee DK, Nguyen T, O'Neill GP, Cheng R, Liu Y, Howard AD, Coulombe N, Tan CP, Tang-Nguyen AT, George SR, O'Dowd BF.

FEBS Lett. 1999 Mar 5;446(1):103-7.

28.

Cloning of a novel G-protein-coupled receptor GPR 51 resembling GABAB receptors expressed predominantly in nervous tissues and mapped proximal to the hereditary sensory neuropathy type 1 locus on chromosome 9.

Ng GY, McDonald T, Bonnert T, Rigby M, Heavens R, Whiting P, Chateauneuf A, Coulombe N, Kargman S, Caskey T, Evans J, O'neill GP, Liu Q.

Genomics. 1999 Mar 15;56(3):288-95.

PMID:
10087195
29.

Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity.

Ng GY, Clark J, Coulombe N, Ethier N, Hebert TE, Sullivan R, Kargman S, Chateauneuf A, Tsukamoto N, McDonald T, Whiting P, Mezey E, Johnson MP, Liu Q, Kolakowski LF Jr, Evans JF, Bonner TI, O'Neill GP.

J Biol Chem. 1999 Mar 19;274(12):7607-10.

30.

Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3.

Kolakowski LF Jr, O'Neill GP, Howard AD, Broussard SR, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao LL, Hreniuk DL, Tan CP, Evans J, Abramovitz M, Chateauneuf A, Coulombe N, Ng G, Johnson MP, Tharian A, Khoshbouei H, George SR, Smith RG, O'Dowd BF.

J Neurochem. 1998 Dec;71(6):2239-51.

31.
32.

The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs.

Greig GM, Francis DA, Falgueyret JP, Ouellet M, Percival MD, Roy P, Bayly C, Mancini JA, O'Neill GP.

Mol Pharmacol. 1997 Nov;52(5):829-38.

PMID:
9351974
33.

Investigation of human cyclooxygenase-2 glycosylation heterogeneity and protein expression in insect and mammalian cell expression systems.

Percival MD, Bastien L, Griffin PR, Kargman S, Ouellet M, O'Neill GP.

Protein Expr Purif. 1997 Apr;9(3):388-98.

PMID:
9126611
34.

Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells.

Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, Kargman S, Kennedy BP, Ouellet M, Skorey K, O'Neill GP, Vickers PJ, Riendeau D.

Inflamm Res. 1997 Feb;46(2):51-9.

PMID:
9085144
35.

Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs.

Mancini JA, Vickers PJ, O'Neill GP, Boily C, Falgueyret JP, Riendeau D.

Mol Pharmacol. 1997 Jan;51(1):52-60.

PMID:
9016346
36.

Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells.

Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP.

Biochem Pharmacol. 1996 Oct 11;52(7):1113-25.

PMID:
8831731
37.
38.

Epitope-labeled soluble human interleukin-5 (IL-5) receptors. Affinity cross-link labeling, IL-5 binding, and biological activity.

Brown PM, Tagari P, Rowan KR, Yu VL, O'Neill GP, Middaugh CR, Sanyal G, Ford-Hutchinson AW, Nicholson DW.

J Biol Chem. 1995 Dec 8;270(49):29236-43.

39.

Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.

Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, Metters KM.

Mol Pharmacol. 1995 Aug;48(2):352-61.

PMID:
7651369
40.

Characterization of arachidonic-acid-metabolizing enzymes in adult Schistisoma mansoni.

Abdel Baset H, O'Neill GP, Ford-Hutchinson AW.

Mol Biochem Parasitol. 1995 Jul;73(1-2):31-41.

PMID:
8577345
41.

Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S.

Cancer Res. 1995 Jun 15;55(12):2556-9.

42.

A single-step purification of biologically active recombinant human interleukin-5 from a baculovirus expression system.

Brown PM, Scheid MP, O'Neill GP, Tagari PC, Nicholson DW.

Protein Expr Purif. 1995 Feb;6(1):63-71.

PMID:
7756840
43.

Selective inhibitors of COX-2.

O'Neill GP, Kennedy BP, Mancini JA, Kargman S, Ouellet M, Yergey J, Falgueyret JP, Cromlish WA, Payette P, Chan CC, et al.

Agents Actions Suppl. 1995;46:159-68. Review.

PMID:
7610986
44.

Purification and characterization of recombinant human cyclooxygenase-2.

Percival MD, Ouellet M, Vincent CJ, Yergey JA, Kennedy BP, O'Neill GP.

Arch Biochem Biophys. 1994 Nov 15;315(1):111-8.

PMID:
7979387
45.
46.

Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid.

O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, Abramovitz M, Kennedy BP, Ouellet M, Cromlish W, et al.

Mol Pharmacol. 1994 Feb;45(2):245-54.

PMID:
8114674
47.

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues.

O'Neill GP, Ford-Hutchinson AW.

FEBS Lett. 1993 Sep 13;330(2):156-60.

48.

Cross-species comparison of 5-lipoxygenase-activating protein.

Vickers PJ, O'Neill GP, Mancini JA, Charleson S, Abramovitz M.

Mol Pharmacol. 1992 Dec;42(6):1014-9.

PMID:
1480129
49.

The nucleotide sequence of a voltage-gated chloride channel from the electric organ of Torpedo californica.

O'Neill GP, Grygorczyk R, Adam M, Ford-Hutchinson AW.

Biochim Biophys Acta. 1991 Dec 2;1129(1):131-4.

PMID:
1721838
50.

delta-Aminolevulinic acid dehydratase deficiency can cause delta-aminolevulinate auxotrophy in Escherichia coli.

O'Neill GP, Thorbjarnardóttir S, Michelsen U, Pálsson S, Söll D, Eggertsson G.

J Bacteriol. 1991 Jan;173(1):94-100.

Supplemental Content

Loading ...
Support Center